Anti-IgE terapija astme i alergijskog rinitisa omalizumabom

Other - Other

• Title (english): Anti-IgE therapy with omalizumab in asthma and allergic rhinitis
• Author: Slavica Dodig
• Author: Darko Richter
• Author: Ivana Cepelak
• Author: Bojan Benko
• Author's institution: University of Zagreb; Faculty of Pharmacy and Biochemistry; (Department of medical biochemistry and haematology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Pharmacy; Medical Biochemistry

Abstract (croatian)

Opisani su farmakologija, djelotvornost, doziranje, nuspojave i ekonomičnost primjene anti IgE antitijela – omalizumab. Omalizumab je generičko ime za ljudsko / mišje kimerično (rekombinantno humanizirano) monoklonalno IgG antitijelo. Anti-IgE sprječava vezanje IgE na efektorske stanice i sprječava upalni odgovor posredovan s IgE. Nakon subkutane primjene sporo se apsorbira te dostiže vršnu koncentraciju u serumu nakon 7 do 8 dana. Uz preporučene doze koncentracija slobodnog IgE u serumu smanjuje se unutar jednog sata. Doziranje se podešava prema tjelesnoj masi i koncentraciji IgE-a u serumu. Omalizumab je djelotvoran kao dopunska terapija u pacijenata (starijih od 12 godina) sa slabo kontroliranom umjerenom do teškom alergijskom astmom odnosno s alergijskim rinitisom. Smanjuje potrebu za inhalacijskim kortikosteroidima te pogoršanje astme. Dobro se podnosi, ali sigurnost primjene, kako u odraslih tako i u djece, treba još ispitati.

Abstract (english)

The pharmacology, efficacy, dosage, adverse effects, and economics of anti IgE (omalizumab) are discussed. Omalizumab is the generic name for the human/murine chimeric (recombinant humanized) monoclonal IgG antibody. Anti-IgE prevents IgE from attaching to effector cells, and thereby blunts IgE-mediated inflammatory responses. After subcutaneous administration its absorption is slow, reaching peak concentration in serum after an average of 7-8 days. At recommended doses, serum free IgE levels decrease within 1 hour following the first dose and maintained between doses. Dose and dosing frequency are adjusted according to body mass and serum total IgE concentration before the start of treatment. Omalizumab administered subcutaneously is an effective treatment for add-on therapy in patients with poorly controlled, moderate-to-severe allergic asthma and allergic rhinitis (adults and adolescents >12 years). It reduces the requirement for inhaled corticosteroids while protecting against disease exacerbation. Omalizumab is well tolerated, but the safety profile requires long-term assessment in adults as well as in children.

• Keywords (croatian): astma; alergijski rinitis; terapija; anti-IgE; omalizumab
• Keywords (english): asthma; allergic rhinitis; therapy; anti-IgE; omalizumab
• Language: croatian
• Language: english
• Publication type: Other - Other
• Publication status: Published
• Peer review: Peer review - international
• Publication version: Published version
• Journal title: Acta Pharmaceutica
• Numbering: vol. 55, no. 2, pp. 123-138
• p-ISSN: 1330-0075
• e-ISSN: 1846-9558
• URN:NBN: urn:nbn:hr:163:360976
• Publication: 2005
• Document URL: https://hrcak.srce.hr/16751
• Type of resource: Text
• Access conditions: Open access
• Created on: 2020-04-08 15:03:19